Minerva Neurosciences, Inc. NERV

NERV Company Overview

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system (CNS) disorders. The company primarily targets neurological and psychiatric conditions with significant unmet medical needs, including schizophrenia, major depressive disorder, insomnia, and Parkinson’s disease-related symptoms. Its operations are concentrated in the biotechnology and pharmaceutical industries, with a research emphasis on compounds that modulate brain signaling pathways and neuropsychiatric function.

The company’s principal value driver has historically been its pipeline of proprietary CNS drug candidates, particularly roluperidone, a compound investigated for the treatment of negative symptoms associated with schizophrenia. Minerva was founded in 2007 and became publicly traded on the Nasdaq under the ticker NERV. Over time, the company evolved from a broader CNS development platform into a more focused organization centered on advancing late-stage neuropsychiatric assets and preserving strategic flexibility through licensing and development partnerships.